Level Biotechnology (3118) - Net Assets
Based on the latest financial reports, Level Biotechnology (3118) has net assets worth NT$562.82 Million TWD (≈ $17.73 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$799.85 Million ≈ $25.20 Million USD) and total liabilities (NT$237.03 Million ≈ $7.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Level Biotechnology tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$562.82 Million |
| % of Total Assets | 70.37% |
| Annual Growth Rate | 1.0% |
| 5-Year Change | 5.76% |
| 10-Year Change | N/A |
| Growth Volatility | 2.54 |
Level Biotechnology - Net Assets Trend (2017–2024)
This chart illustrates how Level Biotechnology's net assets have evolved over time, based on quarterly financial data. See Level Biotechnology liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Level Biotechnology (2017–2024)
The table below shows the annual net assets of Level Biotechnology from 2017 to 2024. For live valuation and market cap data, see 3118 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$559.91 Million ≈ $17.64 Million |
+1.90% |
| 2023-12-31 | NT$549.47 Million ≈ $17.31 Million |
+1.30% |
| 2022-12-31 | NT$542.40 Million ≈ $17.09 Million |
-0.45% |
| 2021-12-31 | NT$544.84 Million ≈ $17.17 Million |
+2.91% |
| 2020-12-31 | NT$529.43 Million ≈ $16.68 Million |
+3.05% |
| 2019-12-31 | NT$513.75 Million ≈ $16.19 Million |
+3.00% |
| 2018-12-31 | NT$498.78 Million ≈ $15.71 Million |
-4.50% |
| 2017-12-31 | NT$522.28 Million ≈ $16.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Level Biotechnology's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 53.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$66.48 Million | 11.87% |
| Other Components | NT$493.43 Million | 88.13% |
| Total Equity | NT$559.91 Million | 100.00% |
Level Biotechnology Competitors by Market Cap
The table below lists competitors of Level Biotechnology ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Auking Mining Ltd
AU:AKN
|
$31.97 Million |
|
TeraGo Inc.
TO:TGO
|
$31.98 Million |
|
Reino Capital SA
WAR:RNC
|
$32.01 Million |
|
Nordic Iron Ore
ST:NIO
|
$32.01 Million |
|
Hankukpackage Co. Ltd
KQ:037230
|
$31.95 Million |
|
Poulaillon SA
PA:ALPOU
|
$31.94 Million |
|
Fridenson
TA:FRDN
|
$31.94 Million |
|
Australian Mines Ltd
AU:AUZ
|
$31.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Level Biotechnology's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 549,472,000 to 559,914,000, a change of 10,442,000 (1.9%).
- Net income of 64,811,000 contributed positively to equity growth.
- Dividend payments of 55,170,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$64.81 Million | +11.58% |
| Dividends Paid | NT$55.17 Million | -9.85% |
| Other Changes | NT$801.00K | +0.14% |
| Total Change | NT$- | 1.90% |
Book Value vs Market Value Analysis
This analysis compares Level Biotechnology's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.81x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.94x to 1.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$16.09 | NT$31.25 | x |
| 2018-12-31 | NT$15.37 | NT$31.25 | x |
| 2019-12-31 | NT$15.83 | NT$31.25 | x |
| 2020-12-31 | NT$16.24 | NT$31.25 | x |
| 2021-12-31 | NT$16.68 | NT$31.25 | x |
| 2022-12-31 | NT$16.60 | NT$31.25 | x |
| 2023-12-31 | NT$16.83 | NT$31.25 | x |
| 2024-12-31 | NT$17.25 | NT$31.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Level Biotechnology utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.58%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.86%
- • Asset Turnover: 0.88x
- • Equity Multiplier: 1.48x
- Recent ROE (11.58%) is above the historical average (10.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 13.08% | 11.83% | 0.79x | 1.40x | NT$16.09 Million |
| 2018 | 7.80% | 6.19% | 0.92x | 1.36x | NT$-10.96 Million |
| 2019 | 9.23% | 7.42% | 0.85x | 1.46x | NT$-3.98 Million |
| 2020 | 10.96% | 8.63% | 0.87x | 1.46x | NT$5.10 Million |
| 2021 | 12.51% | 10.07% | 0.86x | 1.45x | NT$13.69 Million |
| 2022 | 10.78% | 9.86% | 0.73x | 1.50x | NT$4.23 Million |
| 2023 | 11.45% | 9.52% | 0.80x | 1.50x | NT$7.96 Million |
| 2024 | 11.58% | 8.86% | 0.88x | 1.48x | NT$8.82 Million |
Industry Comparison
This section compares Level Biotechnology's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,723,372,111
- Average return on equity (ROE) among peers: 6.35%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Level Biotechnology (3118) | NT$562.82 Million | 13.08% | 0.42x | $31.95 Million |
| Apex Biotechnology Corp (1733) | $1.75 Billion | 11.53% | 0.52x | $92.11 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.32 Billion | 9.26% | 0.78x | $190.85 Million |
| Panion & BF Biotech Inc (1760) | $1.93 Billion | 5.40% | 0.53x | $161.80 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $2.50 Billion | 21.29% | 0.26x | $85.54 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $969.06 Million | 16.12% | 0.26x | $101.71 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $44.44 Million |
| Medigen Biotechnology (3176) | $3.46 Billion | -15.61% | 0.30x | $146.59 Million |
| Sagittarius Life Science (3205) | $588.38 Million | -12.60% | 0.26x | $112.36 Million |
| Genovate Biotechnology Co Ltd (4130) | $2.25 Billion | 1.74% | 0.18x | $112.45 Million |
About Level Biotechnology
Level Biotechnology Inc. engages in marketing and distributing cell culture, immunology, and molecular biology products in Taiwan. It markets and distributes biomedical precision equipment. The company also provides services in the areas of mammalian and genetic toxicology, pharmacology, biocompatibility, and model animal production. In addition, it offers preclinical research services to the bio… Read more